Compare SUPV & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUPV | OMER |
|---|---|---|
| Founded | 1887 | 1994 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.4M | 844.6M |
| IPO Year | 2015 | 2008 |
| Metric | SUPV | OMER |
|---|---|---|
| Price | $8.69 | $19.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $13.00 | ★ $32.50 |
| AVG Volume (30 Days) | 662.2K | ★ 2.2M |
| Earning Date | 05-26-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $86.20 | N/A |
| Revenue Next Year | $25.12 | $233.22 |
| P/E Ratio | ★ N/A | $24.61 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.54 | $3.94 |
| 52 Week High | $13.55 | $19.65 |
| Indicator | SUPV | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 50.77 | 71.42 |
| Support Level | $7.70 | $18.00 |
| Resistance Level | $8.92 | $19.65 |
| Average True Range (ATR) | 0.44 | 0.88 |
| MACD | 0.12 | -0.14 |
| Stochastic Oscillator | 77.27 | 74.55 |
Grupo Supervielle SA a diversified financial services group in Argentina. It offers a broad range of financial products and services including lending, savings and investments, insurance, payments and cash management services, car loans, and asset management, positioning itself as a one-stop destination for financial needs. It operates exclusively in Argentina, through the Bank, which serves as its main banking subsidiary, delivering a comprehensive suite of financial services to retail, SMEs and corporate customers. Its segments include Personal & Business Banking; Corporate Banking; Bank Treasury; Insurance; and Asset Management and Other Services (which includes IOL invertironline). The majority of the revenue is derived from Personal & Business Banking segment.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.